Myriad Genetics partners with SOPHiA GENETICS on prostate PrGIS CDx
Myriad Genetics said it is collaborating with SOPHiA GENETICS to advance a prostate cancer genomic instability score (PrGIS) with AstraZeneca, targeting clinical-trial use and potential companion diagnostic deployment via Myriad’s MyChoice CDx and SOPHiA’s decentralized platform.